Cargando…
mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells
BACKGROUND: Glioblastoma multiforme (GBM), the most common and most aggressive type of primary adult brain tumour, responds poorly to conventional treatment. Temozolomide (TMZ) chemotherapy remains the most commonly used treatment, despite a large proportion of tumours displaying TMZ resistance. 60%...
Autores principales: | Smalley, Sarah, Chalmers, Anthony J, Morley, Simon J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061125/ https://www.ncbi.nlm.nih.gov/pubmed/24909675 http://dx.doi.org/10.1186/1476-4598-13-144 |
Ejemplares similares
-
EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019) -
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
por: Papavassiliou, Kostas A., et al.
Publicado: (2021) -
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013) -
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018) -
Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)